Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ALT

Altimmune Inc

Feb 13 • 04:00PM ET

4.53

-0.04 -0.88 %

Healthcare • Biotechnology • USA • NASD

Peers: NVAX INO VXRT XFOR ADMA AGEN BCRX ANIX DTIL AVIR

| Held by: XBI VTI IWM VXF IBB IWO FESM VTWO IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-1.07	Insider Own	0.71%	Shs Outstand	104.34M	Perf Week	-6.98%
Market Cap	567.30M	Forward P/E	-	EPS next Y	-1.21	Insider Trans	3.56%	Shs Float	103.61M	Perf Month	8.37%
Enterprise Value	372.38M	PEG	-	EPS next Q	-0.23	Inst Own	50.02%	Short Float	23.32%	Perf Quarter	7.09%
Income	-83.92M	P/S	28365.00	EPS this Y	27.16%	Inst Trans	5.85%	Short Ratio	4.95	Perf Half Y	23.10%
Sales	0.02M	P/B	2.33	EPS next Y	-23.82%	ROA	-45.82%	Short Interest	24.16M	Perf YTD	25.48%
Book/sh	1.94	P/C	2.69	EPS next 5Y	8.87%	ROE	-52.61%	52W High	7.73 -41.40%	Perf Year	-27.29%
Cash/sh	1.68	P/FCF	-	EPS past 3/5Y	17.12% 3.48%	ROIC	-41.70%	52W Low	2.90 56.21%	Perf 3Y	-65.71%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-83.45% -67.83%	Gross Margin	-495.00%	Volatility	5.15% 9.53%	Perf 5Y	-79.61%
Dividend TTM	-	EV/Sales	18619.00	EPS Y/Y TTM	31.25%	Oper. Margin	-452310.00%	ATR (14)	0.39	Perf 10Y	-91.91%
Dividend Ex-Date	-	Quick Ratio	17.18	Sales Y/Y TTM	-61.54%	Profit Margin	-419575.00%	RSI (14)	44.21	Recom	1.70
Dividend Gr. 3/5Y	- -	Current Ratio	17.18	EPS Q/Q	33.85%	SMA20	-9.98%	Beta	0.13	Target Price	19.75
Payout	-	Debt/Eq	0.09	Sales Q/Q	0.00%	SMA50	-3.63%	Rel Volume	0.80	Prev Close	4.57
Employees	59	LT Debt/Eq	0.08	Earnings	Nov 06 BMO	SMA200	-0.53%	Avg Volume	4.88M	Price	4.53
IPO	Oct 06, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.82% 257.14%	Trades		Volume	3,885,967	Change	-0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$20
Jul-10-25	Resumed	Goldman	Sell	$1
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy	$18
Nov-12-24	Initiated	UBS	Buy	$26
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral	$13
Mar-22-23	Downgrade	Goldman	Buy → Neutral	$20 → $6
Dec-01-22	Initiated	Goldman	Buy	$20
Dec-29-21	Resumed	Jefferies	Buy	$30
Jun-02-21	Initiated	H.C. Wainwright	Buy	$35
Feb-11-21	Initiated	Guggenheim	Buy	$36
Dec-14-20	Initiated	Jefferies	Buy	$25
Nov-12-20	Reiterated	B. Riley Securities	Buy	$31 → $28
Sep-25-20	Initiated	B. Riley FBR	Buy	$31
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight	$80
Jul-28-20	Initiated	JMP Securities	Mkt Outperform	$50
Feb-24-20	Resumed	ROTH Capital	Buy	$13
Jul-19-19	Initiated	ROTH Capital	Buy	$8.30

Show Previous Ratings

Feb-02-26 09:55AM	Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development (Insider Monkey)
Jan-29-26 05:54PM	Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire) +9.80%
01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire)
Jan-28-26 04:13PM	Altimmune (ALT) Shares Slide On $75 Million Stock Offering (Benzinga) -17.15%
Jan-27-26 09:25PM	Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire) +9.19%
02:06PM	Loading…
Jan-23-26 02:06PM	Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly (24/7 Wall St.)
09:40AM	Unusually active option classes on open January 22nd (TipRanks)
Jan-06-26 11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks)
Jan-05-26 07:30AM	Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH (GlobeNewswire) +16.52%
Dec-29-25 10:15AM	3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround (Zacks)
Dec-19-25 06:30AM	Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial (GlobeNewswire) -22.77%
Dec-11-25 09:55AM	Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? (Zacks)
Dec-01-25 07:30AM	Altimmune Announces CEO Transition and Succession Plan (GlobeNewswire) -6.27%
Nov-26-25 07:30AM	Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-25-25 09:55AM	Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know (Zacks)
08:51AM	Loading…
Nov-11-25 08:51AM	Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-08-25 06:05AM	Altimmune price target lowered to $14 from $15 at Citizens JMP (TipRanks)
Nov-07-25 08:05AM	Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-06-25 07:00AM	Altimmune Announces Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire) +5.07%
Nov-05-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 07:30AM	Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder (GlobeNewswire)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
Oct-30-25 07:30AM	Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 (GlobeNewswire)
Oct-20-25 07:30AM	Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Oct-01-25 08:45AM	Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
Sep-30-25 10:52AM	Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ALT (Business Wire)
Sep-29-25 07:30AM	Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide (GlobeNewswire) -5.25%
Sep-23-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Sep-15-25 07:30AM	Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer (GlobeNewswire)
Sep-09-25 09:00AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT (PR Newswire)
08:45AM	Loading…
Sep-02-25 08:45AM	Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
Aug-26-25 08:45AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
07:30AM	Altimmune to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-25 07:30AM	Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
Aug-14-25 04:34PM	Investors in Altimmune, Inc. (ALT): Protect Your Rights - Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
Aug-13-25 04:24PM	Altimmune, Inc. (ALT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
03:07AM	Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ... (GuruFocus.com)
Aug-12-25 07:00AM	Altimmune Announces Second Quarter 2025 Financial Results and Business Update (GlobeNewswire) +7.10%
Aug-11-25 07:30AM	Altimmune Board of Directors Appoints Jerry Durso as Chairman (GlobeNewswire)
Aug-05-25 07:30AM	Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 (GlobeNewswire)
Jul-25-25 08:46AM	Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-09-25 07:30AM	Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) (GlobeNewswire)
01:19AM	Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial (Insider Monkey)
Jun-26-25 07:00AM	Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH (GlobeNewswire) -53.18%
Jun-25-25 07:12PM	Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 (GlobeNewswire) +7.23%
Jun-18-25 09:53AM	Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. (Motley Fool)
Jun-13-25 07:30AM	Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
May-21-25 11:17AM	Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential (Insider Monkey)
May-19-25 07:30AM	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
May-14-25 09:18AM	Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension (TipRanks)
07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-13-25 07:00AM	Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital (GlobeNewswire)
07:00AM	Altimmune Announces First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
May-12-25 01:01PM	Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings? (Zacks) +7.51%
06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-09-25 09:55AM	How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% (Zacks)
May-08-25 07:30AM	Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress (GlobeNewswire) +8.21%
May-06-25 07:30AM	Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 (GlobeNewswire) -7.37%
May-01-25 07:30AM	Altimmune to Present at Upcoming EASL International Liver Congress 2025 (GlobeNewswire)
Apr-30-25 07:30AM	Altimmune to Participate in the Citizens Life Sciences Conference (GlobeNewswire)
04:51AM	Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
04:51AM	Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Mar-22-25 06:44AM	Buying These Dirt-Cheap Stocks Could Be a Brilliant Move (Motley Fool)
Mar-19-25 04:33PM	Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts (InsiderMonkey)
Mar-06-25 07:30AM	Altimmune to Host Virtual R&D Day on March 13, 2025 (GlobeNewswire)
Mar-03-25 07:30AM	Altimmune to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -9.92%
Feb-27-25 07:00AM	Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) +8.08%
Feb-25-25 07:30AM	Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors (GlobeNewswire)
Feb-20-25 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 (GlobeNewswire)
Jan-29-25 07:30AM	Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-28-24 03:39PM	Jim Cramer on Altimmune, Inc. (ALT): and#8216;Healthcare Is So Out Of Fashion' (Insider Monkey)
Dec-19-24 07:30AM	Altimmune Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-17-24 08:13PM	Lightning Round: Ford's warranty problems will come back to haunt it, says Jim Cramer (CNBC TV) -6.67% -5.95%
Dec-03-24 06:22PM	Altimmune CEO on what's next for its experimental obesity drug (CNBC TV) +12.06%
Dec-02-24 07:30AM	Altimmune to Present at the Cachexia Regulatory and Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (GlobeNewswire)
07:30AM	Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders (GlobeNewswire)
Nov-26-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-15-24 11:00AM	Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 (GlobeNewswire) -9.99%
Nov-12-24 07:00AM	Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +29.12%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
07:30AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 07:30AM	Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity (GlobeNewswire)
Nov-06-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 07:30AM	Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024 (GlobeNewswire) +9.49%
Oct-01-24 07:30AM	Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-30-24 07:30AM	Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire) -5.10%
Sep-10-24 01:09PM	CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.09%
07:45AM	Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-03-24 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Aug-08-24 07:00AM	Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +15.09%
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -7.02%
Aug-01-24 07:30AM	Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology (GlobeNewswire) +6.70%
Jul-09-24 06:42AM	7 Bullish Stock Picks With the Potential to Turn $5K Into $50K (InvestorPlace)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 07:30AM	Altimmune to Participate at Leerink Partners Therapeutics Forum (GlobeNewswire) -6.39%
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)
01:55AM	Altimmune, Inc. (ALT): Why Are Hedge Funds Shorting This Biopharmaceutical Stock? (Insider Monkey)

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Roberts M Scot	Chief Scientific Officer	Feb 02 '26	Option Exercise	0.00	7,775	0	115,153	Feb 03 04:15 PM
Roberts M Scot	Chief Scientific Officer	Jan 30 '26	Option Exercise	0.00	9,275	0	104,670	Feb 03 04:15 PM
Garg Vipin K	Director	Jan 30 '26	Option Exercise	0.00	26,775	0	429,225	Feb 02 04:15 PM
Jordt Raymond M	Chief Business Officer	Jan 27 '26	Option Exercise	0.00	15,850	0	69,765	Jan 29 04:15 PM
Garg Vipin K	Director	Jan 27 '26	Option Exercise	0.00	41,200	0	420,348	Jan 29 04:10 PM
Roberts M Scot	Chief Scientific Officer	Jan 27 '26	Option Exercise	0.00	15,850	0	100,143	Jan 29 04:05 PM
Jordt Raymond M	Chief Business Officer	Jan 25 '26	Option Exercise	0.00	14,600	0	57,770	Jan 27 07:10 AM
Garg Vipin K	Director	Jan 25 '26	Option Exercise	0.00	42,050	0	397,132	Jan 27 07:05 AM
Roberts M Scot	Chief Scientific Officer	Jan 25 '26	Option Exercise	0.00	14,600	0	88,666	Jan 27 07:00 AM
Pisano Wayne	Director	Jan 08 '26	Buy	4.08	5,000	20,410	13,498	Jan 09 04:10 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '26	Option Exercise	0.00	9,375	0	45,645	Jan 05 04:10 PM
Jorkasky Diane	Director	Dec 29 '25	Buy	3.80	527	2,003	527	Dec 29 04:10 PM
GILL JOHN	Director	Dec 23 '25	Buy	4.10	12,500	51,250	12,500	Dec 23 04:10 PM
Durso Jerome Benedict	Director	Dec 22 '25	Buy	4.13	12,500	51,569	12,500	Dec 22 04:10 PM
WEAVER GREGORY L	Chief Financial Officer	Nov 11 '25	Option Exercise	0.00	18,750	0	28,750	Nov 12 04:07 PM
Sohn Catherine A.	Director	Mar 17 '25	Buy	5.78	1,000	5,784	1,000	Mar 18 04:15 PM
WEAVER GREGORY L	Chief Financial Officer	Mar 13 '25	Buy	5.20	10,000	51,996	10,000	Mar 14 07:27 AM

Open in Screener

JAZZ

Jazz Pharmaceuticals plc

Feb 13 • 04:00PM ET

166.31

+0.02 0.01 %

Healthcare • Biotechnology • Ireland • NASD

JAZZ Jazz Pharmaceuticals plc daily Stock Chart

Peers: VRTX REGN BIIB INCY GILD BMRN NBIX EXEL UTHR SAGE

| Held by: IJH VTI VB VBR VXF MDY IJK COWG SPMD CALF

Index	-	P/E	-	EPS (ttm)	-6.07	Insider Own	4.67%	Shs Outstand	60.74M	Perf Week	0.49%
Market Cap	10.11B	Forward P/E	7.54	EPS next Y	22.04	Insider Trans	-4.55%	Shs Float	57.93M	Perf Month	-2.63%
Enterprise Value	13.49B	PEG	1.15	EPS next Q	6.52	Inst Own	100.44%	Short Float	9.78%	Perf Quarter	21.65%
Income	-368.48M	P/S	2.43	EPS this Y	-60.80%	Inst Trans	-1.43%	Short Ratio	4.80	Perf Half Y	42.55%
Sales	4.16B	P/B	2.55	EPS next Y	169.06%	ROA	-3.12%	Short Interest	5.66M	Perf YTD	-2.17%
Book/sh	65.18	P/C	4.94	EPS next 5Y	6.58%	ROE	-9.06%	52W High	182.99 -9.12%	Perf Year	21.55%
Cash/sh	33.67	P/FCF	7.56	EPS past 3/5Y	- -1.00%	ROIC	-4.42%	52W Low	95.49 74.16%	Perf 3Y	9.82%
Dividend Est.	-	EV/EBITDA	11.23	Sales past 3/5Y	9.56% 13.48%	Gross Margin	73.01%	Volatility	2.36% 2.51%	Perf 5Y	-0.72%
Dividend TTM	-	EV/Sales	3.24	EPS Y/Y TTM	-179.96%	Oper. Margin	12.39%	ATR (14)	4.44	Perf 10Y	46.17%
Dividend Ex-Date	-	Quick Ratio	1.44	Sales Y/Y TTM	4.14%	Profit Margin	-8.86%	RSI (14)	50.00	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	1.65	EPS Q/Q	19.88%	SMA20	-0.18%	Beta	0.25	Target Price	221.07
Payout	0.00%	Debt/Eq	1.37	Sales Q/Q	6.74%	SMA50	-0.61%	Rel Volume	0.40	Prev Close	166.29
Employees	2800	LT Debt/Eq	1.11	Earnings	Feb 24 AMC	SMA200	22.93%	Avg Volume	1.18M	Price	166.31
IPO	Jun 01, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.72% 1.35%	Trades		Volume	477,880	Change	0.01%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Downgrade	UBS	Buy → Neutral	$188
Jul-15-25	Initiated	Deutsche Bank	Buy	$152
Mar-07-25	Upgrade	UBS	Neutral → Buy	$145 → $179
Feb-26-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$130 → $170
Dec-12-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$140 → $175
Jun-05-24	Initiated	Goldman	Buy	$169
Jan-03-24	Initiated	Robert W. Baird	Outperform	$160
Nov-27-23	Downgrade	UBS	Buy → Neutral	$170 → $135
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight	$184 → $140
Dec-09-22	Upgrade	Goldman	Neutral → Buy	$192 → $190
Jun-14-22	Initiated	UBS	Buy	$194
Apr-06-22	Downgrade	Goldman	Buy → Neutral	$202 → $196
Nov-19-21	Resumed	Goldman	Buy	$198
Oct-07-21	Resumed	Jefferies	Buy	$172
Oct-05-21	Initiated	Citigroup	Buy	$200
Sep-23-21	Initiated	Needham	Buy	$220
May-19-21	Resumed	JP Morgan	Overweight	$183 → $206
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$186

Show Previous Ratings

Feb-11-26 08:36AM	Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock? (Zacks)
Feb-10-26 04:15PM	Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 (PR Newswire)
Feb-09-26 07:51AM	Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-03-26 07:56AM	New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings (Zacks)
06:55AM	Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial (Insider Monkey)
12:39PM	Loading…
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-27-26 12:22PM	Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? (Motley Fool)
Jan-26-26 10:15AM	Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? (Zacks)
Jan-16-26 06:24AM	Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading (BioPharma Dive)
Jan-15-26 12:41PM	JPM26: Jazz sells PRV for $200m, targets deals in 2026 (Pharmaceutical Technology)
Jan-13-26 07:43AM	Jazz Pharmaceuticals price target raised to $235 from $210 at Needham (TipRanks)
Jan-09-26 12:19PM	Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 (MarketBeat)
Jan-08-26 07:50PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) -5.38%
04:05PM	Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer (PR Newswire)
Jan-06-26 01:32PM	Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit (PR Newswire)
10:37PM	Loading…
Dec-28-25 10:37PM	Reflecting On Pharmaceuticals Stocks' Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) (StockStory)
Dec-17-25 11:03PM	3 Reasons JAZZ is Risky and 1 Stock to Buy Instead (StockStory)
04:15PM	Jazz Pharmaceuticals to Participate in Upcoming Investor Events (PR Newswire)
Dec-05-25 11:30AM	Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue? (Zacks)
09:00AM	Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting (PR Newswire)
07:12AM	Trials, Sales Wins Sends Jazz Pharmaceuticals Higher (FX Empire)
Dec-02-25 04:05PM	Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Nov-26-25 09:13AM	Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner (Zacks)
Nov-24-25 09:41AM	Booking, Carvana upgraded: Wall Street's top analyst calls (The Fly)
09:20AM	Here are Mondays Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More (24/7 Wall St.)
Nov-20-25 01:37AM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Nov-18-25 04:15PM	Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference (PR Newswire) +6.13%
12:16PM	JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data (Zacks)
03:38AM	Zymeworks to change course, pursue royalty-driven biotech model (BioPharma Dive)
12:43AM	Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial (Insider Monkey)
07:29PM	Loading…
Nov-17-25 07:29PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) +20.57%
04:44PM	Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer (Investor's Business Daily)
04:13PM	Stocks to Watch Recap: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal)
11:41AM	Why Is Jazz Pharmaceuticals (JAZZ) Stock Soaring Today (StockStory)
09:35AM	Stocks to Watch Monday: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal)
09:15AM	Why Jazz (JAZZ) International Revenue Trends Deserve Your Attention (Zacks)
08:10AM	Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. (Barrons.com)
06:00AM	Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (PR Newswire)
Nov-12-25 12:36AM	The Top 5 Analyst Questions From Jazz Pharmaceuticals's Q3 Earnings Call (StockStory)
Nov-11-25 07:45AM	Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025 (PR Newswire)
Nov-06-25 10:50AM	JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View (Zacks)
12:33AM	JAZZ Q3 Deep Dive: New Drug Launches and Portfolio Expansion Drive Strong Results (StockStory)
12:01AM	Jazz Pharmaceuticals PLC (JAZZ) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Nov-05-25 07:00PM	Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:32PM	Jazz: Q3 Earnings Snapshot (Associated Press Finance)
04:25PM	Jazz Pharmaceuticals's (NASDAQ:JAZZ) Q3: Beats On Revenue (StockStory)
04:05PM	Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance (PR Newswire)
Nov-04-25 10:28AM	AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
Nov-03-25 10:17PM	Earnings To Watch: Jazz Pharmaceuticals (JAZZ) Reports Q3 Results Tomorrow (StockStory)
Oct-29-25 10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline (Zacks)
Oct-28-25 04:05PM	Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors (PR Newswire)
Oct-24-25 12:02AM	3 Reasons to Sell JAZZ and 1 Stock to Buy Instead (StockStory)
Oct-22-25 04:15PM	Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 (PR Newswire)
Oct-21-25 06:55AM	Iambic partners with Jazz; Merck breaks ground on $3B plant (BioPharma Dive)
Oct-16-25 02:14PM	Praxis Precision's tremor-drug trial has succeeded where others have failed. The stock is skyrocketing. (MarketWatch)
Oct-06-25 01:13PM	Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer (Zacks)
Oct-02-25 06:37PM	FDA Approves Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (PR Newswire)
01:53AM	Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data (Insider Monkey)
Oct-01-25 11:10AM	Headlines Boost Pharma Stocks. Charts of Pfizer, Johnson & Johnson, Jazz Pharmaceuticals Speak to Rally Into Year End (Barrons.com)
Sep-30-25 09:45AM	Can Auvelity Drive Axsome's Growth Through the Rest of 2025? (Zacks)
Sep-27-25 12:59AM	Piper Sandler Reaffirms Jazz Pharmaceuticals (JAZZ) Price Target Ahead of Trial Data (Insider Monkey)
Sep-24-25 08:45AM	Here's Why JAZZ Stock Is an Unconventional Cannabis Investment (Zacks)
Sep-23-25 07:11PM	Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval (Insider Monkey)
Sep-22-25 07:45AM	Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses (PR Newswire)
Sep-16-25 09:30AM	Jazz Pharmaceuticals plc (JAZZ) Wins FDA Nod for Modeyso in Rare Pediatric Brain Tumors (Insider Monkey)
Sep-09-25 07:45AM	Modeyso (dordaviprone) Included in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma (PR Newswire)
Sep-02-25 01:34AM	Jazz Pharmaceuticals (JAZZ) Price Target Raised After Modeyso Commercial Strategy Update (Insider Monkey)
Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
05:04AM	Jazz Pharmaceuticals plc (JAZZ) Wins FDA Accelerated Approval for Modeyso Brain Cancer Therapy (Insider Monkey)
Aug-28-25 11:49PM	Jazz Pharmaceuticals (JAZZ) Sings License with Saniona for SAN2355 (Insider Monkey)
Aug-22-25 11:57PM	BofA Raises PT on Jazz Pharmaceuticals (JAZZ) to $225 From $217 (Insider Monkey)
06:27AM	FDA cancels adcomm on Biohaven drug; Catalent lays off staff (BioPharma Dive)
Aug-21-25 04:15PM	Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference (PR Newswire)
09:49AM	JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug (Zacks)
Aug-20-25 04:15PM	Jazz Pharmaceuticals to Host Modeyso (dordaviprone) Investor Webcast on August 27, 2025 (PR Newswire)
07:30AM	Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 (PR Newswire)
Aug-19-25 07:17PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Aug-17-25 11:35PM	Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks (StockStory)
Aug-14-25 04:03AM	United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis (GlobeNewswire)
Aug-13-25 04:30PM	Onco360 adds Modeyso (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider (GlobeNewswire)
12:16AM	The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals's Q2 Earnings Call (StockStory)
Aug-12-25 11:48PM	JAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook (StockStory)
Aug-08-25 09:15AM	Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock (Zacks)
05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive)
Aug-07-25 03:35PM	Why Jazz Pharmaceuticals (JAZZ) Stock Is Trading Up Today (StockStory) +5.81%
05:00AM	FDA gives accelerated approval to Jazz Pharmas diffuse midline glioma therapy (Pharmaceutical Technology)
Aug-06-25 07:08PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) -6.42%
03:07PM	Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma (PR Newswire)
09:22AM	JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut (Zacks)
03:29AM	Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... (GuruFocus.com)
Aug-05-25 06:30PM	Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
06:13PM	Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Q2 In Line With Expectations But Stock Drops (StockStory)
05:15PM	Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Jazz: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance (PR Newswire)
11:36AM	AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
Aug-03-25 11:01PM	Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Jul-30-25 11:44AM	Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains 'Buy' Rating (Insider Monkey)
10:00AM	Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth (Zacks)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Henderson Mary Elizabeth	SVP, Technical Operations	Dec 09 '25	Sale	169.51	2,238	379,366	19,508	Dec 11 05:19 PM
MARY ELIZABETH HENDERSON	Officer	Dec 09 '25	Proposed Sale	169.51	2,238	379,365		Dec 09 06:52 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 05 '25	Option Exercise	140.67	4,500	633,015	11,512	Dec 09 05:25 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 05 '25	Sale	171.20	4,660	797,783	7,012	Dec 09 05:25 PM
PATRICIA CARR	Officer	Dec 05 '25	Proposed Sale	171.20	4,660	797,783		Dec 05 04:03 PM
O'Keefe Kenneth W	Director	Dec 02 '25	Proposed Sale	176.59	1,249	220,561		Dec 01 08:55 PM
COZADD BRUCE C	Director	Nov 26 '25	Option Exercise	123.36	77,500	9,560,400	470,832	Dec 01 06:14 PM
COZADD BRUCE C	Director	Nov 26 '25	Sale	177.81	77,500	13,780,337	393,332	Dec 01 06:14 PM
BRUCE COZADD	Director	Nov 26 '25	Proposed Sale	177.81	77,500	13,780,337		Nov 26 05:37 PM
McSharry Heather Ann	Director	Nov 20 '25	Option Exercise	138.08	3,415	471,543	23,864	Nov 24 05:47 PM
McSharry Heather Ann	Director	Nov 20 '25	Sale	177.78	3,415	607,127	20,449	Nov 24 05:47 PM
COZADD BRUCE C	Director	Nov 18 '25	Sale	181.09	18,000	3,259,538	390,826	Nov 20 08:03 PM
Carr Patricia	SVP, Chief Accounting Officer	Nov 18 '25	Option Exercise	136.18	5,250	714,945	12,262	Nov 20 06:13 PM
Carr Patricia	SVP, Chief Accounting Officer	Nov 18 '25	Sale	182.06	5,319	968,402	7,012	Nov 20 06:13 PM
Winningham Rick E	Director	Nov 18 '25	Sale	180.86	5,500	994,728	8,893	Nov 20 05:54 PM
HEATHER MCSHARRY	Director	Nov 20 '25	Proposed Sale	177.78	3,415	607,127		Nov 20 04:05 PM
Henderson Mary Elizabeth	Officer	Nov 19 '25	Proposed Sale	127.23	2,961	376,740		Nov 19 08:59 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Nov 17 '25	Sale	168.26	7,159	1,204,573	72,628	Nov 19 08:31 PM
Bruce C Cozadd	Officer	Nov 18 '25	Proposed Sale	181.09	18,000	3,259,537		Nov 18 07:08 PM
RICK WINNINGHAM	Director	Nov 18 '25	Proposed Sale	180.86	5,500	994,728		Nov 18 05:20 PM
PATRICIA CARR	Officer	Nov 18 '25	Proposed Sale	182.06	5,319	968,402		Nov 18 04:59 PM
ROBERT IANNONE	Officer	Nov 17 '25	Proposed Sale	168.26	7,159	1,204,573		Nov 17 04:06 PM
COZADD BRUCE C	Director	Oct 03 '25	Sale	140.00	3,500	490,000	408,826	Oct 03 09:27 PM
COZADD BRUCE C	Director	Oct 01 '25	Sale	131.78	2,000	263,560	412,326	Oct 03 09:27 PM
Bruce C Cozadd	Officer	Oct 03 '25	Proposed Sale	140.00	3,500	490,000		Oct 03 04:10 PM
COZADD BRUCE C	Director	Sep 02 '25	Sale	128.62	6,000	771,690	429,973	Sep 04 05:48 PM
Winningham Rick E	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 03:02 PM
Kennedy Patrick	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:56 PM
ENRIGHT PATRICK G	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:46 PM
RIEDEL NORBERT G	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:40 PM
Smith Mark Douglas	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:33 PM
Hamill Laura	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:26 PM
O'Keefe Kenneth W	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:20 PM
Cook Jennifer E.	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:13 PM
McSharry Heather Ann	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:06 PM
ORiordan Anne	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:00 PM
COZADD BRUCE C	Chairman & CEO	Aug 01 '25	Sale	113.21	1,000	113,210	435,973	Aug 05 04:54 PM
COZADD BRUCE C	Officer	Aug 01 '25	Proposed Sale	121.80	9,000	1,096,210		Aug 01 03:28 PM
COZADD BRUCE C	Chairman & CEO	Jul 01 '25	Sale	107.63	1,000	107,630	436,973	Jul 03 02:56 PM
COZADD BRUCE C	Officer	Jul 01 '25	Proposed Sale	107.63	1,000	107,630		Jul 01 04:15 PM
COZADD BRUCE C	Chairman & CEO	Jun 03 '25	Sale	110.00	500	55,000	437,973	Jun 04 04:50 PM
COZADD BRUCE C	Chairman & CEO	Jun 02 '25	Sale	107.90	500	53,950	438,473	Jun 04 04:50 PM
COZADD BRUCE C	Officer	Jun 02 '25	Proposed Sale	108.95	1,000	108,950		Jun 02 05:03 PM
Mulligan Seamus	Director	May 09 '25	Buy	98.26	100,000	9,826,120	100,000	May 13 06:51 PM
Mulligan Seamus	Director	May 12 '25	Buy	103.00	1,621	166,962	101,621	May 13 06:51 PM
COZADD BRUCE C	Chairman & CEO	May 01 '25	Sale	116.35	1,000	116,350	439,307	May 05 07:00 PM
COZADD BRUCE C	Chairman & CEO	May 02 '25	Sale	120.00	500	60,000	438,807	May 05 07:00 PM
COZADD BRUCE C	Officer	May 01 '25	Proposed Sale	117.57	1,500	176,350		May 01 04:09 PM
COZADD BRUCE C	Chairman & CEO	Apr 01 '25	Sale	123.75	1,500	185,625	440,307	Apr 03 05:32 PM
COZADD BRUCE C	Officer	Apr 01 '25	Proposed Sale	125.31	2,000	250,625		Apr 01 04:32 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 10 '25	Sale	138.41	2,403	332,605	79,621	Mar 12 02:24 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 10 '25	Sale	137.81	1,140	157,103	7,012	Mar 11 06:17 PM
Iannone Robert	Officer	Mar 10 '25	Proposed Sale	145.00	1,767	256,215		Mar 10 06:01 PM
Carr Patricia	Officer	Mar 10 '25	Proposed Sale	137.81	1,140	157,103		Mar 10 05:36 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 07 '25	Sale	138.60	7,080	981,298	82,024	Mar 07 06:49 PM
ROBERT IANNONE	Officer	Mar 07 '25	Proposed Sale	138.73	5,466	758,305		Mar 07 05:14 PM
Iannone Robert	Officer	Mar 07 '25	Proposed Sale	142.26	4,017	571,476		Mar 07 05:04 PM
Henderson Mary Elizabeth	Officer	Mar 07 '25	Proposed Sale	139.00	1,295	180,005		Mar 07 03:15 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Option Exercise	113.77	4,813	547,562	12,737	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Sale	144.42	4,813	695,075	8,237	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 28 '25	Sale	143.29	773	110,767	9,485	Mar 03 07:21 PM
Patil Neena M	EVP & Chief Legal Officer	Feb 27 '25	Sale	144.87	3,800	550,506	33,318	Mar 03 07:18 PM
COZADD BRUCE C	Chairman & CEO	Mar 03 '25	Sale	144.25	6,500	937,625	464,058	Mar 03 07:13 PM
COZADD BRUCE C	Officer	Mar 03 '25	Proposed Sale	144.25	6,500	937,625		Mar 03 04:44 PM
Carr Patricia	Officer	Feb 28 '25	Proposed Sale	143.30	773	110,767		Feb 28 05:43 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	139.00	1,641	228,099		Feb 27 08:05 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	144.42	4,813	695,075		Feb 27 05:04 PM
Patil Neena M	Officer	Feb 27 '25	Proposed Sale	144.87	3,800	550,518		Feb 27 04:56 PM

ALT

Altimmune Inc

JAZZ

Jazz Pharmaceuticals plc

Upgrade your FINVIZ experience